Cardio Diagnostics Holdings Launches Epigenetic-Genetic Blood Test

Tuesday, February 28, 2023

Cardio Diagnostics Holdings announced the launch of PrecisionCHD™, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.

PrecisionCHD™ is the first integrated epigenetic-genetic-based blood test for the early detection of coronary heart disease.

PrecisionCHD gives providers a complement to traditional CHD diagnostic solutions. The test is non-invasive, simple, and provides an informative, personalised patient report of CHD status. With the U.S. launch of PrecisionCHD, this technology will first be available exclusively for existing customers, with a nationwide roll-out expected shortly thereafter.

Cardiovascular disease (CVD) continues to be the leading cause of death in the United States, with coronary heart disease (CHD) being the most common type of CVD and the primary cause of heart attacks. According to the American Heart Association, nearly 400,000 deaths in 2020 are attributable to CHD, and over 800,000 Americans have a heart attack yearly. Cardio Diagnostics’ new patent-pending test, PrecisionCHD, aids in the early detection of coronary heart disease to better enable the management of this condition to prevent a symptomatic event such as a heart attack.